Cargando…

Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting

Background: Schistosomiasis is a neglected tropical disease caused by helminths of the genus Schistosoma. Morbidity markers and cytological observations such as squamous metaplastic cells, inflammatory cells, and hyperkeratotic cells in the urine of S. haematobium-infected children may suggest disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetteh-Quarcoo, Patience B., Ampong, Asamoah, Dayie, Nicholas T. K. D., Ahenkorah, John, Udofia, Emilia A., Afutu, Emmanuel, Aryee, Robert, Niriwa, Benjamin P., Kotey, Fleischer C. N., Donkor, Eric S., Ayeh-Kumi, Patrick F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883892/
https://www.ncbi.nlm.nih.gov/pubmed/35225947
http://dx.doi.org/10.3390/medsci10010014
_version_ 1784660036177362944
author Tetteh-Quarcoo, Patience B.
Ampong, Asamoah
Dayie, Nicholas T. K. D.
Ahenkorah, John
Udofia, Emilia A.
Afutu, Emmanuel
Aryee, Robert
Niriwa, Benjamin P.
Kotey, Fleischer C. N.
Donkor, Eric S.
Ayeh-Kumi, Patrick F.
author_facet Tetteh-Quarcoo, Patience B.
Ampong, Asamoah
Dayie, Nicholas T. K. D.
Ahenkorah, John
Udofia, Emilia A.
Afutu, Emmanuel
Aryee, Robert
Niriwa, Benjamin P.
Kotey, Fleischer C. N.
Donkor, Eric S.
Ayeh-Kumi, Patrick F.
author_sort Tetteh-Quarcoo, Patience B.
collection PubMed
description Background: Schistosomiasis is a neglected tropical disease caused by helminths of the genus Schistosoma. Morbidity markers and cytological observations such as squamous metaplastic cells, inflammatory cells, and hyperkeratotic cells in the urine of S. haematobium-infected children may suggest disease severity. They may also help predict severe forms of clinical presentation, such as bladder cancer in later years, among infected ones who miss out on early detection and treatment. Insights into possible changes in the morbidity markers and cytological observations in the urine of these S. haematobium-infected children before and after treatment would be of high clinical importance. Aim: The aim of this study was to identify changes/dynamics in morbidity markers and cytological abnormalities in the urine deposits of S. haematobium-infected children, pre- and post-praziquantel treatment. Methodology: This was a longitudinal study involving baseline and follow-up sampling among basic school children living in schistosomiasis-endemic communities. Urine samples were collected from 520 children at baseline and examined for S. haematobium ova by microscopy, while urine chemistry analyses were used for the examination of morbidity markers. The cytological analyses involved cytopathological examination of the urine deposits. Children whose urine showed positivity for S. haematobium eggs were treated with a single oral dose of praziquantel (40 mg/kg), after which urine chemistry and cytological analyses were repeated weekly for comparison with baseline, until the eighth week. Results: Morbidity markers such as hematuria, proteinuria, and leukocyturia were detected both at baseline and post-treatment among the infected children (30/520). Hematuria was the predominant parameter (90%, 27/30) detected at baseline, followed by proteinuria (53.3%, 16/30). Leukocyturia was the rarest parameter detected at baseline (13.3%, 4/30). However, almost all these parameters declined gradually post-treatment. Regarding cytological analyses, inflammatory cells were observed most (70.0%, 21/30) at baseline. For hyperkeratotic cells and squamous metaplastic cells, 46.7% and 26.7% were respectively observed at baseline, all of which gradually declined during the weekly follow-ups. Notably, squamous metaplastic cells persisted in all the participants from Week 1 through Week 3 post-treatment, but declined gradually thereafter. Conclusions: Morbidity markers and cytological observations in the children gradually decreased after treatment. Therefore, we continue to recommend routine cytological screening for urogenital schistosomiasis patients at hospitals in S. haematobium-endemic locations using both baseline and follow-up samples to detect these abnormalities early and monitor changes that may be occurring after treatment. Such changes may be useful in assessing treatment progress in infected persons.
format Online
Article
Text
id pubmed-8883892
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88838922022-03-01 Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting Tetteh-Quarcoo, Patience B. Ampong, Asamoah Dayie, Nicholas T. K. D. Ahenkorah, John Udofia, Emilia A. Afutu, Emmanuel Aryee, Robert Niriwa, Benjamin P. Kotey, Fleischer C. N. Donkor, Eric S. Ayeh-Kumi, Patrick F. Med Sci (Basel) Article Background: Schistosomiasis is a neglected tropical disease caused by helminths of the genus Schistosoma. Morbidity markers and cytological observations such as squamous metaplastic cells, inflammatory cells, and hyperkeratotic cells in the urine of S. haematobium-infected children may suggest disease severity. They may also help predict severe forms of clinical presentation, such as bladder cancer in later years, among infected ones who miss out on early detection and treatment. Insights into possible changes in the morbidity markers and cytological observations in the urine of these S. haematobium-infected children before and after treatment would be of high clinical importance. Aim: The aim of this study was to identify changes/dynamics in morbidity markers and cytological abnormalities in the urine deposits of S. haematobium-infected children, pre- and post-praziquantel treatment. Methodology: This was a longitudinal study involving baseline and follow-up sampling among basic school children living in schistosomiasis-endemic communities. Urine samples were collected from 520 children at baseline and examined for S. haematobium ova by microscopy, while urine chemistry analyses were used for the examination of morbidity markers. The cytological analyses involved cytopathological examination of the urine deposits. Children whose urine showed positivity for S. haematobium eggs were treated with a single oral dose of praziquantel (40 mg/kg), after which urine chemistry and cytological analyses were repeated weekly for comparison with baseline, until the eighth week. Results: Morbidity markers such as hematuria, proteinuria, and leukocyturia were detected both at baseline and post-treatment among the infected children (30/520). Hematuria was the predominant parameter (90%, 27/30) detected at baseline, followed by proteinuria (53.3%, 16/30). Leukocyturia was the rarest parameter detected at baseline (13.3%, 4/30). However, almost all these parameters declined gradually post-treatment. Regarding cytological analyses, inflammatory cells were observed most (70.0%, 21/30) at baseline. For hyperkeratotic cells and squamous metaplastic cells, 46.7% and 26.7% were respectively observed at baseline, all of which gradually declined during the weekly follow-ups. Notably, squamous metaplastic cells persisted in all the participants from Week 1 through Week 3 post-treatment, but declined gradually thereafter. Conclusions: Morbidity markers and cytological observations in the children gradually decreased after treatment. Therefore, we continue to recommend routine cytological screening for urogenital schistosomiasis patients at hospitals in S. haematobium-endemic locations using both baseline and follow-up samples to detect these abnormalities early and monitor changes that may be occurring after treatment. Such changes may be useful in assessing treatment progress in infected persons. MDPI 2022-02-17 /pmc/articles/PMC8883892/ /pubmed/35225947 http://dx.doi.org/10.3390/medsci10010014 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tetteh-Quarcoo, Patience B.
Ampong, Asamoah
Dayie, Nicholas T. K. D.
Ahenkorah, John
Udofia, Emilia A.
Afutu, Emmanuel
Aryee, Robert
Niriwa, Benjamin P.
Kotey, Fleischer C. N.
Donkor, Eric S.
Ayeh-Kumi, Patrick F.
Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title_full Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title_fullStr Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title_full_unstemmed Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title_short Dynamics in Morbidity Markers and Cytological Observations Made in Urine of Schistosoma haematobium-Infected Children: Pre- and Post-Praziquantel Treatment in an Endemic Setting
title_sort dynamics in morbidity markers and cytological observations made in urine of schistosoma haematobium-infected children: pre- and post-praziquantel treatment in an endemic setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883892/
https://www.ncbi.nlm.nih.gov/pubmed/35225947
http://dx.doi.org/10.3390/medsci10010014
work_keys_str_mv AT tettehquarcoopatienceb dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT ampongasamoah dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT dayienicholastkd dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT ahenkorahjohn dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT udofiaemiliaa dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT afutuemmanuel dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT aryeerobert dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT niriwabenjaminp dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT koteyfleischercn dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT donkorerics dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting
AT ayehkumipatrickf dynamicsinmorbiditymarkersandcytologicalobservationsmadeinurineofschistosomahaematobiuminfectedchildrenpreandpostpraziquanteltreatmentinanendemicsetting